PLOD3 as A Potential Drug Target and Biomarker for Leukemia (G8985)

Target Name: PLOD3

NCBI ID: G8985

PLOD3

PLOD3 as A Potential Drug Target and Biomarker for Leukemia

PLOD3 (Promyelocytic leukemia light chain 3) is a protein that is expressed in a variety of tissues, including the bone marrow, spleen, and lymph nodes. It is a component of the B-cell receptor, which is a protein that is responsible for recognizing and responding to foreign substances in the body. PLOD3 is also known as LH3 because it contains a light chain protein that is similar to the LH3 protein found in the leukemia cells.

One of the things that makes PLOD3 an interesting potential drug target is its role in the development and progression of leukemia. Leukemia is a type of cancer that affects the bone marrow, where blood cells are produced. When a person has leukemia, their B-cells, which are responsible for producing antibodies to help fight off infections, are mutated and do not function properly. This can lead to a build-up of cancerous cells in the bone marrow, which can progress to other parts of the body and form tumors.

PLOD3 is involved in the signaling process that regulates the development and progression of leukemia. It is a key regulator of the B-cell receptor, which is responsible for recognizing and responding to foreign substances in the body. When the B-cell receptor recognizes a foreign substance, it sends a signal to the cell to divide and multiply. PLOD3 is part of this signaling process, and it is involved in regulating the number of B-cells that are produced by the bone marrow.

One of the things that makes PLOD3 an interesting potential drug target is its role in the treatment of leukemia. Because PLOD3 is involved in the signaling process that regulates the development and progression of leukemia, targeting it with drugs could potentially help treat the disease. For example, some researchers are investigating whether drugs that target PLOD3 could be used to prevent the development of leukemia in people with a genetic predisposition to the disease.

Another potential use of PLOD3 as a drug target is its role in the regulation of the immune system. The immune system is responsible for protecting the body against infection and disease, and it is an important part of the body's defense against cancer. PLOD3 is involved in the regulation of the immune system by controlling the movement of immune cells. This can help to prevent cancerous cells from being immune to the immune system, which could make them more difficult to detect and treat.

In addition to its potential role in the treatment of leukemia, PLOD3 is also being investigated as a potential biomarker for the disease. Leukemia can be a difficult to diagnose and treat condition, and doctors often have difficulty predicting which patients will respond to treatment and which will not. By using PLOD3 as a biomarker, doctors may be able to identify people with leukemia who are more likely to respond to treatment and those who are less likely to respond. This could help to improve treatment outcomes and save lives.

Overall, PLOD3 is an interesting protein that is being studied as a potential drug target and biomarker for leukemia. Its role in the regulation of the B-cell receptor and the immune system makes it an attractive target for drug development, and its potential as a biomarker for the disease makes it an important area of research. Further research is needed to fully understand the role of PLOD3 in leukemia and to develop effective treatments.

Protein Name: Procollagen-lysine,2-oxoglutarate 5-dioxygenase 3

Functions: Multifunctional enzyme that catalyzes a series of essential post-translational modifications on Lys residues in procollagen (PubMed:11956192, PubMed:12475640, PubMed:18298658, PubMed:30089812, PubMed:18834968). Plays a redundant role in catalyzing the formation of hydroxylysine residues in -Xaa-Lys-Gly- sequences in collagens (PubMed:9582318, PubMed:9724729, PubMed:11956192, PubMed:12475640, PubMed:18298658, PubMed:30089812, PubMed:18834968). Plays a redundant role in catalyzing the transfer of galactose onto hydroxylysine groups, giving rise to galactosyl 5-hydroxylysine (PubMed:12475640, PubMed:18298658, PubMed:30089812, PubMed:18834968). Has an essential role by catalyzing the subsequent transfer of glucose moieties, giving rise to 1,2-glucosylgalactosyl-5-hydroxylysine residues (PubMed:10934207, PubMed:11896059, PubMed:11956192, PubMed:12475640, PubMed:18298658, PubMed:30089812, PubMed:18834968). Catalyzes hydroxylation and glycosylation of Lys residues in the MBL1 collagen-like domain, giving rise to hydroxylysine and 1,2-glucosylgalactosyl-5-hydroxylysine residues (PubMed:25419660). Essential for normal biosynthesis and secretion of type IV collagens (PubMed:18834968) (Probable). Essential for normal formation of basement membranes (By similarity)

The "PLOD3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PLOD3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets